AR110753A1 - Inhibidores selectivos de jak1 - Google Patents
Inhibidores selectivos de jak1Info
- Publication number
- AR110753A1 AR110753A1 ARP180100104A ARP180100104A AR110753A1 AR 110753 A1 AR110753 A1 AR 110753A1 AR P180100104 A ARP180100104 A AR P180100104A AR P180100104 A ARP180100104 A AR P180100104A AR 110753 A1 AR110753 A1 AR 110753A1
- Authority
- AR
- Argentina
- Prior art keywords
- methyl
- chosen
- ethyl
- selective inhibitors
- jak1 selective
- Prior art date
Links
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 title 1
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 title 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se desvelan en el presente documento compuestos y sales farmacéuticamente aceptables de los mismos. Además, se desvelan composiciones farmacéuticas que comprenden compuestos y métodos de uso de los mismos. Reivindicación 1: Un compuesto de fórmula (1), en la que: cada uno de R¹, R³, y R⁴ se escoge individualmente de hidrógeno y metilo; R² se escoge de hidrógeno, metilo, y -CH₂CH₂OH; n es 1 ó 2; R⁵ se escoge de metilo, etilo, y -CH₂OR⁸; R⁶ se escoge de metilo, cloro, y flúor; R⁷ se selecciona de metilo, etilo, y ciclopropilo; y R⁸ se selecciona de metilo, etilo, y bencilo; o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762447057P | 2017-01-17 | 2017-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR110753A1 true AR110753A1 (es) | 2019-05-02 |
Family
ID=61024756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP180100104A AR110753A1 (es) | 2017-01-17 | 2018-01-17 | Inhibidores selectivos de jak1 |
Country Status (38)
| Country | Link |
|---|---|
| US (4) | US10961228B2 (es) |
| EP (2) | EP3571192B1 (es) |
| JP (3) | JP6986086B2 (es) |
| KR (2) | KR102585048B1 (es) |
| CN (2) | CN115925693B (es) |
| AR (1) | AR110753A1 (es) |
| AU (1) | AU2018209667B2 (es) |
| CA (1) | CA3049175A1 (es) |
| CL (1) | CL2019001993A1 (es) |
| CO (1) | CO2019007888A2 (es) |
| CR (1) | CR20190332A (es) |
| DK (1) | DK3571192T3 (es) |
| DO (1) | DOP2019000184A (es) |
| EA (1) | EA037067B1 (es) |
| EC (1) | ECSP19051352A (es) |
| ES (1) | ES2938648T3 (es) |
| FI (1) | FI3571192T3 (es) |
| HR (1) | HRP20230069T1 (es) |
| HU (1) | HUE061064T2 (es) |
| IL (1) | IL267851B (es) |
| JO (1) | JOP20190174B1 (es) |
| LT (1) | LT3571192T (es) |
| MA (1) | MA47301B1 (es) |
| MX (2) | MX390625B (es) |
| MY (1) | MY199735A (es) |
| NI (1) | NI201900077A (es) |
| PE (1) | PE20191108A1 (es) |
| PH (1) | PH12019501639B1 (es) |
| PL (1) | PL3571192T3 (es) |
| PT (1) | PT3571192T (es) |
| RS (1) | RS63981B1 (es) |
| SG (1) | SG11201906222WA (es) |
| SI (1) | SI3571192T1 (es) |
| SM (1) | SMT202300051T1 (es) |
| TW (1) | TWI753089B (es) |
| UA (1) | UA124246C2 (es) |
| WO (1) | WO2018134213A1 (es) |
| ZA (1) | ZA201906875B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3571192T3 (fi) | 2017-01-17 | 2023-03-06 | Astrazeneca Ab | Jak1-selektiivisiä inhibiittoreita |
| PL3514153T3 (pl) | 2017-01-26 | 2022-01-17 | Hanmi Pharm. Co., Ltd. | Związek pirymidynowy i jego zastosowanie farmaceutyczne |
| CN112424187B (zh) * | 2018-07-18 | 2024-06-21 | 阿斯利康(瑞典)有限公司 | 抑制jak的化合物的昔萘酸盐 |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| KR102669660B1 (ko) * | 2018-09-21 | 2024-05-27 | 상하이 엔노바바이오 파마슈티컬스 씨오 엘티디. | 키나아제 억제 활성을 가진 방향족 헤테로고리 화합물 |
| PH12021551985A1 (en) | 2019-02-22 | 2022-08-22 | Hanmi Pharmaceutical Co Ltd | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia |
| CA3134174A1 (en) * | 2019-04-19 | 2020-10-22 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Jak1 selective kinase inhibitor |
| US12350265B2 (en) | 2019-06-27 | 2025-07-08 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents |
| EP4132920B1 (en) * | 2020-04-09 | 2025-08-13 | Disarm Therapeutics, Inc. | Indazole derivatives as inhibitors of sarm1 |
| WO2022111499A1 (zh) * | 2020-11-26 | 2022-06-02 | 深圳铂立健医药有限公司 | 一种酰胺化合物、药物组合物及其应用 |
| CA3211124A1 (en) * | 2021-02-26 | 2022-09-01 | Tyra Biosciences, Inc. | Aminopyrimidine compounds and methods of their use |
| US12240836B2 (en) * | 2022-07-05 | 2025-03-04 | Dong-A St Co., Ltd. | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof |
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| EP4648776A1 (en) * | 2023-01-11 | 2025-11-19 | Pfizer Inc. | Compositions and methods for the treatment and/or prevention of type 1 diabetes |
| CN115974845B (zh) * | 2023-01-19 | 2024-09-20 | 奥锐特药业股份有限公司 | 奥希替尼中间体的制备方法 |
| AU2024236890A1 (en) * | 2023-03-16 | 2025-09-25 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of asthma |
| GB202316063D0 (en) | 2023-10-20 | 2023-12-06 | Astrazeneca Ab | Dosing regime |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2007114080A (ru) | 2004-10-13 | 2008-11-27 | Вайет (Us) | N-бензилсульфонил-замещенные аналоги анилинопиримидина |
| GB2431927B (en) * | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| CN101421250A (zh) * | 2006-01-30 | 2009-04-29 | 埃克塞里艾克西斯公司 | 作为jak-2调节剂的4-芳基-2-氨基-嘧啶或4-芳基-2-氨基烷基-嘧啶及包含它们的药物组合物 |
| JP2010518025A (ja) * | 2007-02-05 | 2010-05-27 | アミラ ファーマシューティカルス，インコーポレーテッド | ５−リポキシゲナーゼ活性化タンパク質（ｆｌａｐ）インヒビターとしての逆インドール |
| JP2010540641A (ja) * | 2007-10-05 | 2010-12-24 | アミラ ファーマシューティカルス，インコーポレーテッド | ５−リポキシゲナーゼ活性化タンパク質（ｆｌａｐ）阻害剤 |
| WO2009046416A1 (en) * | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| SI3354652T1 (sl) | 2010-03-10 | 2020-08-31 | Incyte Holdings Corporation | Derivati piperidin-4-il azetidina kot inhibitorji JAK1 |
| CA2812087A1 (en) * | 2010-09-15 | 2012-03-22 | F. Hoffmann-La Roche Ag | Azabenzothiazole compounds, compositions and methods of use |
| JP2016539927A (ja) | 2013-10-24 | 2016-12-22 | アッヴィ・インコーポレイテッド | Ｊａｋ１選択的阻害剤とその使用 |
| RU2760359C2 (ru) | 2015-09-25 | 2021-11-24 | Дизал (Цзянсу) Фармасьютикалз Ко., Лимитед | Соединения и способы для ингибирования JAK |
| FI3571192T3 (fi) * | 2017-01-17 | 2023-03-06 | Astrazeneca Ab | Jak1-selektiivisiä inhibiittoreita |
-
2018
- 2018-01-16 FI FIEP18701296.8T patent/FI3571192T3/fi active
- 2018-01-16 CN CN202211243959.9A patent/CN115925693B/zh active Active
- 2018-01-16 SG SG11201906222WA patent/SG11201906222WA/en unknown
- 2018-01-16 CN CN201880018044.3A patent/CN110461830B/zh active Active
- 2018-01-16 PL PL18701296.8T patent/PL3571192T3/pl unknown
- 2018-01-16 MY MYPI2019004083A patent/MY199735A/en unknown
- 2018-01-16 RS RS20230130A patent/RS63981B1/sr unknown
- 2018-01-16 CR CR20190332A patent/CR20190332A/es unknown
- 2018-01-16 MX MX2019008435A patent/MX390625B/es unknown
- 2018-01-16 MX MX2022002976A patent/MX418519B/es unknown
- 2018-01-16 CA CA3049175A patent/CA3049175A1/en active Pending
- 2018-01-16 EP EP18701296.8A patent/EP3571192B1/en active Active
- 2018-01-16 HR HRP20230069TT patent/HRP20230069T1/hr unknown
- 2018-01-16 JO JOP/2019/0174A patent/JOP20190174B1/ar active
- 2018-01-16 LT LTEPPCT/EP2018/051038T patent/LT3571192T/lt unknown
- 2018-01-16 UA UAA201909176A patent/UA124246C2/uk unknown
- 2018-01-16 PT PT187012968T patent/PT3571192T/pt unknown
- 2018-01-16 SM SM20230051T patent/SMT202300051T1/it unknown
- 2018-01-16 KR KR1020197023855A patent/KR102585048B1/ko active Active
- 2018-01-16 MA MA47301A patent/MA47301B1/fr unknown
- 2018-01-16 US US16/478,168 patent/US10961228B2/en active Active
- 2018-01-16 WO PCT/EP2018/051038 patent/WO2018134213A1/en not_active Ceased
- 2018-01-16 SI SI201830849T patent/SI3571192T1/sl unknown
- 2018-01-16 EP EP22209765.1A patent/EP4219470A1/en active Pending
- 2018-01-16 DK DK18701296.8T patent/DK3571192T3/da active
- 2018-01-16 KR KR1020237032917A patent/KR102659213B1/ko active Active
- 2018-01-16 PE PE2019001401A patent/PE20191108A1/es unknown
- 2018-01-16 JP JP2019537377A patent/JP6986086B2/ja active Active
- 2018-01-16 AU AU2018209667A patent/AU2018209667B2/en active Active
- 2018-01-16 EA EA201991700A patent/EA037067B1/ru unknown
- 2018-01-16 HU HUE18701296A patent/HUE061064T2/hu unknown
- 2018-01-16 ES ES18701296T patent/ES2938648T3/es active Active
- 2018-01-16 PH PH1/2019/501639A patent/PH12019501639B1/en unknown
- 2018-01-17 AR ARP180100104A patent/AR110753A1/es unknown
- 2018-01-17 TW TW107101685A patent/TWI753089B/zh active
-
2019
- 2019-07-04 IL IL267851A patent/IL267851B/en unknown
- 2019-07-15 CL CL2019001993A patent/CL2019001993A1/es unknown
- 2019-07-17 DO DO2019000184A patent/DOP2019000184A/es unknown
- 2019-07-17 EC ECSENADI201951352A patent/ECSP19051352A/es unknown
- 2019-07-17 NI NI201900077A patent/NI201900077A/es unknown
- 2019-07-23 CO CONC2019/0007888A patent/CO2019007888A2/es unknown
- 2019-10-18 ZA ZA2019/06875A patent/ZA201906875B/en unknown
-
2021
- 2021-03-01 US US17/188,097 patent/US11897869B2/en active Active
- 2021-11-26 JP JP2021191658A patent/JP7394820B2/ja active Active
-
2023
- 2023-10-20 JP JP2023180744A patent/JP7626819B2/ja active Active
- 2023-12-13 US US18/538,067 patent/US12473272B2/en active Active
-
2025
- 2025-09-30 US US19/345,428 patent/US20260028329A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR110753A1 (es) | Inhibidores selectivos de jak1 | |
| AR119424A1 (es) | Derivados de 3-oxo-4h-quinoxalina y oxo-1h-naftiridina como inhibidores de parp | |
| AR111820A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación de virus del dengue | |
| AR111233A1 (es) | Inhibidores de tyk2, usos y métodos para la producción de los mismos | |
| ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| AR087711A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y uso de los mismos para el tratamiento de trastornos neurodegenerativos | |
| UY37133A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR090590A1 (es) | COMPUESTOS 1,3,4-OXADIAZOL Y 1,3,4-TIADIAZOL COMO INHIBIDORES DE b-LACTAMASA | |
| AR088535A1 (es) | Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1) | |
| GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
| CR20150371A (es) | Inhibidores de prmt5 y sus usos | |
| AR101189A1 (es) | Heterociclos nitrogenados antiproliferativos y sus métodos de uso | |
| UY33501A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
| AR107927A1 (es) | Compuestos de pirrolidina, sal farmacéuticamente aceptable del mismo, composición farmacéutica que lo comprende y su uso para la fabricación de un medicamento | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR111315A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR100806A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| CO2019006220A2 (es) | Compuestos de pirazolopirimidina y métodos de uso de los mismos | |
| CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
| PE20211246A1 (es) | Compuestos biciclicos para su uso como inhibidores de rip1 quinasa | |
| AR118729A1 (es) | Inhibidor selectivo de la jak1 quinasa | |
| CU20190042A7 (es) | Compuestos derivados de naftiridinona | |
| JOP20190050A1 (ar) | مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي | |
| ECSP20026023A (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk2. |